Literature DB >> 15043709

Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study.

S Pistolesi1, L Boldrini, S Gisfredi, K De Ieso, T Camacci, M Caniglia, G Lupi, P Leocata, F Basolo, R Pingitore, G Parenti, G Fontanini.   

Abstract

Much of the morbidity of intracranial meningiomas is related to the degree of tumour vascularity and the extent of peritumoural vasogenic oedema. Several studies have shown that vascular endothelial growth factor (VEGF) is up-regulated in meningiomas, although its relationship with tumour vasculature is still unclear. In order to better understand the angiogenic assessment of intracranial meningiomas, we analysed its vascular pattern, both as number and as morphologic configuration of microvessels. Moreover, we investigated the mRNA-VEGF expression, relating this expression to vascular pattern. A total of 40 intracranial meningiomas, classified as benign (31 cases), atypical (7 cases), and anaplastic (2 cases) were analysed. RT-PCR analyses of mRNA-VEGF and competitive-PCR were performed. VEGF expression and microvessel density (MVD) were also immunohistochemically investigated. Grade II-III meningiomas showed numerous small microvessels (mean: 34), while the majority of Grade I showed few larger vessels (mean: 13.09) (P = 0.000003). A microvessel pattern overlapping into atypical subtype was found in eignt of the 31 (25.8%) Grade I meningiomas. A significant association was found between grading and vascular pattern (P = 0.0002), as well as between the MVD and the immunohistochemical expression of VEGF (P = 0.0005). The expression of mRNA agreed with the immunohistochemical expression of the protein (P < 0.0001). A total of 39 cases expressed the 121 VEGF isoform and, among these, 28 cases also expressed the 165 isoform. Only 9 cases expressed both isoforms 165 and 189. Grade II and III meningiomas showed a preponderant expression of soluble isoforms (121 and 165). These results prompt us to speculate that the microvessel pattern could underlie a higher metabolic demand, probably due to a rapid growth with a consequent worse clinical behaviour of the tumour. In this sense, the vascular pattern may be used as a prognostic factor, in order to mostly focus attention on those Grade I meningiomas which have a higher likelihood of either recurrence or development of perilesional oedema. The pattern of vasculature itself seems to be dependent on the types of VEGF isoforms: the Grade II-III meningiomas (that presented numerous microvessels) expressed the soluble isoforms 121 and 165, while the isoform 189 was more frequently detected in Grade I meningiomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15043709     DOI: 10.1046/j.0305-1846.2003.00516.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  29 in total

1.  Antibody-based cancer therapies: back to "polyclonals"?

Authors:  Giovanni Paganelli; Rita De Santis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-17       Impact factor: 9.236

2.  Angiogenesis as a predictor of recurrence in meningiomas.

Authors:  Valeria Barresi
Journal:  J Neurooncol       Date:  2010-05-26       Impact factor: 4.130

3.  Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Authors:  Emil Lou; Ashley L Sumrall; Scott Turner; Katherine B Peters; Annick Desjardins; James J Vredenburgh; Roger E McLendon; James E Herndon; Frances McSherry; Julie Norfleet; Henry S Friedman; David A Reardon
Journal:  J Neurooncol       Date:  2012-04-26       Impact factor: 4.130

4.  Expression of endothelin 1 and its angiogenic role in meningiomas.

Authors:  Laura Boldrini; Sabina Pistolesi; Silvia Gisfredi; Silvia Ursino; Greta Alì; Nicola Pieracci; Fulvio Basolo; Giuliano Parenti; Gabriella Fontanini
Journal:  Virchows Arch       Date:  2006-09-30       Impact factor: 4.064

5.  A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.

Authors:  Jeffrey J Raizer; Sean A Grimm; Alfred Rademaker; James P Chandler; Kenji Muro; Irene Helenowski; Laurie Rice; Katie McCarthy; Sandra K Johnston; Maciej M Mrugala; Marc Chamberlain
Journal:  J Neurooncol       Date:  2014-01-22       Impact factor: 4.130

6.  Semaphorin3A immunohistochemical expression in human meningiomas: correlation with the microvessel density.

Authors:  Valeria Barresi; Enrica Vitarelli; Serenella Cerasoli
Journal:  Virchows Arch       Date:  2009-03-19       Impact factor: 4.064

7.  Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma.

Authors:  Patricia Guevara; Elizabeth Escobar-Arriaga; David Saavedra-Perez; Abelardo Martinez-Rumayor; Diana Flores-Estrada; Daniel Rembao; Alejandra Calderon; Julio Sotelo; Oscar Arrieta
Journal:  J Neurooncol       Date:  2009-12-15       Impact factor: 4.130

8.  The Study of MIB-1 LI and CD 34 As A Marker of Proliferative Activity and Angiogenesis in Different Grades of Meningioma.

Authors:  Harishkumar Bohra; Khushi Ram Rathi; Sharmila Dudani; Ashish Bohra; Sumit Vishwakarma; Kavita Sahai
Journal:  J Clin Diagn Res       Date:  2016-08-01

9.  Chordoid meningioma: a report of ten cases.

Authors:  Martha Lilia Tena-Suck; Miguel Angel Collado-Ortìz; Citlaltepetl Salinas-Lara; Rabindhranath García-López; Noemi Gelista; Daniel Rembao-Bojorquez
Journal:  J Neurooncol       Date:  2010-01-22       Impact factor: 4.130

10.  IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  CNS Oncol       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.